THC Therapeutics, Inc.
THCT
$0.0001
-$0.0002-66.67%
OTC PK
| 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 554.66% | -68.87% | -48.70% | -89.74% | -53.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 554.66% | -68.87% | -48.70% | -89.74% | -53.04% |
| Operating Income | -554.66% | 68.87% | 48.70% | 89.74% | 53.04% |
| Income Before Tax | 10.81% | -133.93% | 97.07% | -109.34% | 114.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.81% | -133.93% | 97.07% | -109.34% | 114.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.81% | -133.93% | 97.07% | -109.34% | 114.93% |
| EBIT | -554.66% | 68.87% | 48.70% | 89.74% | 53.04% |
| EBITDA | -557.54% | 68.97% | 48.79% | 89.79% | 52.04% |
| EPS Basic | -6.90% | -133.79% | 97.07% | -109.26% | 114.87% |
| Normalized Basic EPS | -5.56% | -133.85% | 97.04% | -108.82% | 114.75% |
| EPS Diluted | -6.90% | -133.79% | 97.07% | -109.26% | 114.87% |
| Normalized Diluted EPS | -5.56% | -133.85% | 97.04% | -108.82% | 114.75% |
| Average Basic Shares Outstanding | 17.07% | 0.37% | -0.36% | 1.55% | 0.78% |
| Average Diluted Shares Outstanding | 17.07% | 0.37% | -0.36% | 1.55% | 0.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |